Musings from The Power List: Renee Aguiar-Lucander

Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner

September 28, 2026
4 min

The Medicine Maker

Overview

Renee Aguiar-Lucander, CEO of Hansa Biopharma, highlights significant achievements in drug development, particularly the successful Phase 3 study of imlifidase.

Background

The pharmaceutical industry faces challenges in drug development, including lengthy regulatory processes and the need for timely clinical trials.

Data Highlights

No numerical or trial data provided in the article.

Key Findings

Aguiar-Lucander joined Hansa Biopharma as CEO with a focus on recapitalization and drug development.
The US Phase 3 study of imlifidase demonstrated high statistical significance (p < 0.0001).
She advocates for reducing regulatory demands for randomized trials in early-phase studies for rare diseases.
Aguiar-Lucander believes that real-world evidence should be utilized more effectively in drug development.
She predicts a reduction in regulatory review times over the next decade.

Clinical Implications

Improving the efficiency of clinical trials and regulatory processes may enhance the speed at which new therapies reach patients. Emphasizing real-world evidence could also reshape the landscape of drug development, particularly for rare diseases.

Conclusion

Aguiar-Lucander's insights reflect the ongoing challenges and potential advancements in the pharmaceutical industry, particularly regarding regulatory practices and the integration of real-world evidence.